Walden Group Healthcare M&A Blog

The Trump Administration Is Proposing Changes to Medicare Pay For Accountable Care Organization (ACO) Models

08/20/2018
Medicare ACOs began in 2012 and have enrolled more than 10 million beneficiaries so far. If they provide care for less than certain cost targets — while meeting quality of care standards — then they get to share in any of the savings. Commercial insurers and Medicaid have also adopted ACOs in the past decade. About 82% of the 561 Medicare ACOs...
Read More
New Signs of Disrupting Healthcare Delivery. Like Apple, Amazon Is Opening Healthcare Clinics

08/20/2018
The retail giant plans to start a Seattle-based clinic, which will serve a small group of employees at first. The program will then be expanded in early 2019, as part of an ongoing quest to reduce health care costs and cut red tape. Apple also started clinics, initially to serve Apple’s employees in Santa Clara County. Recently, Amazon teamed up...
Read More
Emergent BioSolutions Is Buying PaxVax For $270m

08/10/2018
Emergent BioSolutions, Inc., a $560.8m specialty pharmaceutical company focused on public health threats, is buying PaxVax, Inc., a PE- backed company focuses on specialty vaccines against existing and emerging infectious diseases. The deal expands Emergent's specialty vaccine platform. PaxVax's main product include Vivotif, the only oral...
Read More
The Impact of Trump’s Tariffs

08/07/2018
President Trump’s tariffs on Chinese imports could cost American medical device makers more than $1.5b annually, according to some estimates. MRIs, CT scanners, pacemakers, sonograms and other imaging components were all included in the list of items subject to the 25% tariffs that went into effect on June 6. Also included are a variety of...
Read More
Celgene Acquires Juno Therapeutics For $9b

07/18/2018
Celgene Corp., a $12.5b developer of therapies for cancer and inflammatory diseases is buying Juno Therapeutics Inc., a Seattle-based biotech company making cutting-edge cancer immunotherapy treatments. The Deal expands Celgene’s portfolio of blood-cancer drugs. Juno is one of leaders in a new kind of cancer treatment, known as CAR-T, that...
Read More